Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEPIA-PCI: Otamixaban vs Heparin in PCI
NCT00133731Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of otamixaban in coronary artery disease (CAD) (6 arms), sponsored by Sanofi. Primary endpoint: Death, myocardial infarction, and urgent and non-urgent target vessel revascularization. Started Sep 2004; status: completed.
02
Drugs
otamixaban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00133731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133731.